Astex Pharmaceuticals Announces First Data Showing Early Combination Treatment of HSP90 Inhibitor AT13387 With Targeted Agents Delays Emergence of Resistance in Preclinical Models
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DUBLIN, Calif., July 22, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced data demonstrating for the first time that early treatment with AT13387, a second generation, fully synthetic HSP90 inhibitor, in combination with targeted therapy delays the emergence of resistance. These results were presented at the 8th World Congress of Melanoma July 17 to 20 in Hamburg, Germany.
Help employers find you! Check out all the jobs and post your resume.
DUBLIN, Calif., July 22, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced data demonstrating for the first time that early treatment with AT13387, a second generation, fully synthetic HSP90 inhibitor, in combination with targeted therapy delays the emergence of resistance. These results were presented at the 8th World Congress of Melanoma July 17 to 20 in Hamburg, Germany.
Help employers find you! Check out all the jobs and post your resume.